Nektar update at ASCO likely to be positive, says Piper Jaffray

Piper Jaffray analyst Tyler Van Buren keeps an Overweight rating on Nektar Therapeutics with a $100 price target followign the company’s Q1 results. The analyst looks forward to the melanoma Pivot-02 cohort update at the American Society of Clinical Oncology meeting. He believes the update is likely to be positive.

https://thefly.com/landingPageNews.php?id=2906447